Investigational drug · Phase 2
MDX2003
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "MDX2003"
First trial start
2026
Apr 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MDX2003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoma
- Waldenström Macroglobulinemia (WM)
- DLBCL - Diffuse Large B Cell Lymphoma
- PMBCL
- HGBCL
- FL Lymphoma
- Lymphoplasmacytic Lymphoma
- Follicular Lymphoma (FL)
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "MDX2003" as an intervention, largest first.
- Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaRecruiting
ModeX Therapeutics, An OPKO Health CompanyIndustry
NCT07249905 · 180 participants (planned) · Start Apr 13, 2026 · Primary completion Jan 2028
Drug: MDX2003 · For: Lymphoma; Waldenström Macroglobulinemia (WM); DLBCL - Diffuse Large B Cell Lymphoma and 5 more
Sites: Richmond, Australia; Nedlands, Australia; Haifa, Israel · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Lymphoma
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- OSE2101Phase 32 trials
OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma
- GecacitinibPhase 24 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Lymphoma, Non-small Cell Lung Cancer, Advanced Solid Tumor
- AZD3470Phase 22 trials
AstraZeneca · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- COH04S1GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Phase 22 trials
GeoVax, Inc. · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia
- ASTX660Phase 21 trial
Taiho Oncology, Inc. · Solid Tumors, Lymphoma
- BT02Phase 21 trial
Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma
- CTS3497Phase 21 trial
CytosinLab Therapeutics Co., Ltd. · Solid Tumor, Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.